

# СРАВНИТЕЛЬНОЕ ИССЛЕДОВАНИЕ ЛАБОРАТОРНЫХ АНАЛИЗОВ БОЛЬНЫХ ПЕРЕНЕСШИХ COVID-19 С ИЗМЕНЕНИЯМИ ПИЩЕВАРИТЕЛЬНОЙ СИСТЕМЫ

М.И.Исмоилова.

Ферганский медицинский институт общественного здоровья.

Для цитирования: © Исмоилова М.И.

СРАВНИТЕЛЬНОЕ ИССЛЕДОВАНИЕ ЛАБОРАТОРНЫХ АНАЛИЗОВ БОЛЬНЫХ ПЕРЕНЕСШИХ COVID-19 С ИЗМЕНЕНИЯМИ ПИЩЕВАРИТЕЛЬНОЙ СИСТЕМЫ. ЖКМП.-2023.-Т.4.-№4.-С

Поступила: 25.09.2023

Одобрена: 27.09.2023

Принята к печати: 05.12.2023

**Аннотация:** Были наблюдаемы 100 пациентов, из которых 60 были «относительно излечены» от Covid-19, а 40 не болели инфекцией. У больных, перенесших коронавирус, уровни кальпротектина в фекалиях и интерлейкина-6 в крови были достоверно выше. Это подтверждает, что пациенты с Covid-19 нуждаются в реабилитационных мероприятиях.  
**Ключевые слова:** COVID-19, кальпротектин, интерлейкин-6.

## COVID -19 O‘TKAZGAN VA HAZM TIZIMIDA O‘ZGARISHLAR MAVJUD BEMORLARNING LABORATOR TAHLILLARINI QIYOSIY O‘RGANISH

М.И.Исмоилова.

Farg‘ona jamoat salomatligi tibbiyot instituti.

Izoh: © Ismoilova M.I.

COVID -19 O‘TKAZGAN VA HAZM TIZIMIDA O‘ZGARISHLAR MAVJUD BEMORLARNING LABORATOR TAHLILLARINI QIYOSIY O‘RGANISH.KPTJ.-2023-N.4.-№4-M

Qabul qilindi: 25.09.2023

Ko‘rib chiqildi: 27.09.2023

Nashrga tayyorlandi: 05.12.2023

**Annotatsiya:** Kuzatuvga olingan 100 ta bemorlarning 60 tasi Covid-19 o‘tkazib “nisbiy sog‘aygan” va 40 tasi ushbu infeksiyani o‘tkazmaganlardan iborat bo‘ldi. Ular najasida aniqlangan kalprotektin va qondagi interleykin - 6 ko‘rsatkichlari koronavirus o‘tkazganlarda ishonchli yuqoriligi qayd etildi. Bu Covid-19 o‘tkazgan bemorlar rehabilitatsiya muolajalariga muhtoj ekanliklarini tasdiqlaydi.  
**Kalit so‘zlar:** COVID -19, kalprotektin, interleykin -6.

## COMPARATIVE STUDY OF LABORATORY ANALYSES OF PATIENTS INFECTED WITH COVID-19 AND WITH CHANGES IN THE DIGESTIVE SYSTEM

М.И.Исмоилова.

Fergana medical institute of public health.

For situation: © Ismoilova M.I.

COMPARATIVE STUDY OF LABORATORY ANALYSES OF PATIENTS INFECTED WITH COVID-19 AND WITH CHANGES IN THE DIGESTIVE SYSTEM.JCPM.-2023.P4.№4-A

Received: 25.09.2023

Revised: 27.09.2023

Accepted: 05.12.2023

**Annotation:** 100 patients were observed, of whom 60 were "relatively recovered" from Covid-19 and 40 haven't had the infection. In patients who have had coronavirus infection, the levels of calprotectin in feces and interleukin-6 in the blood were significantly higher. This confirms that COVID-19 patients need rehabilitation measures  
**Keywords:** COVID-19, calprotectin, interleukin-6.

**Introduction:** It has been stated by some researchers, that the first wave of Covid-19 infection affected mainly the respiratory system, and in the second wave, the symptoms of the gastrointestinal system were more characteristic [5, 8]. In 2019, RNA of the coronavirus was isolated for the first time in the USA from the stool of a 35-year-old patient who came with complaints of nausea, vomiting, and diarrhea on the 7th day of the disease [2]. According to a number of studies, the RNA of Covid-19 is detected from the 5th day of the disease, and its peak corresponds to the 11th day. In the feces of some pa-

tients, RNA is preserved even after the respiratory symptoms disappear and the appropriate tests from the respiratory organs are negative [1, 6, 7, 9, 10, 11, 12]. Moreover, although there are opinions that the detection of Covid-19 RNA in feces is not a sign of long-term retention of the infection in the gastrointestinal system [7], there are other data contradictory to that. It is known that the coronavirus enters the body through angiotensin-converting enzyme (ACE 2) receptors. Their high expression is observed not only in alveolar lung cells, but also in gastric, duodenal, and rectal glandular epithelial cells [3, 4, 13] and this in turn, may

cause gastrointestinal symptoms in this infection [9].

It is known that the evaluation of inflammatory processes and permeability in the intestines of patients with COVID-19 is of great practical importance. In recent years, the use of calprotectin has been recommended for this purpose. Calprotectin is a small calcium-binding protein with a molecular weight of 36 kDa and consisting of two heavy and two light polypeptide chains. The protein contains calcium and zinc and has an in vitro bacteriostatic and fungicidal effect. Calprotectin is found in neutrophils in abundance and makes up 60 percent of its cytosol fraction. It is also present in the cytoplasm of monocytes and macrophages. This protein is a product of neutrophilic granulocytes and its detection in feces indicates the existence of an inflammatory process in the intestinal walls. Since calprotectin is considered a stable protein that is degraded very slowly by microorganism proteases, it can be detected in feces. Therefore, it is a reliable marker of "fecal inflammation."

In the literature we studied, there is limited information on the changes observed in patients who "relatively recovered" from COVID-19 with comorbid diseases of various internal organs, including the gastrointestinal system. However, their timely detection and secondary prevention procedures are of great practical importance. Therefore, we aimed to study the state of digestive organs in this group of patients using calprotectin in feces and interleukin-6 in blood.


**Materials and methods** of the study: In accordance with the aim of the study, 100 patients with gastrointestinal symptoms were observed. 42 of them (42%) were men and 58 (58%) were women. Patients were divided into 2 groups. The first group consisted of patients "relatively recovered" from COVID-19 with no detected immunoglobulin M but with gastrointestinal symptoms (27 men and 33 women; average age  $55.06 \pm 2.1$  years). The second, i.e. control group, consisted of patients, who did not have Covid-19 but had gastrointestinal symptoms (15 men and 25 women; average age  $63.4 \pm 1.5$  years) The levels of calprotectin in feces and interleukin-6 in the blood of patients involved in the study were measured:

Calprotectin was in feces evaluated in mgs by "sandwich" method (ELISA) using diagnostic kit RIDASCREEN Calprotectin immunoenzymatic test (R-Biopharm, Germany).

In order to evaluate serum interleukin-6 (IL-6) levels, a package of 96 tests by the company "VECTOR-BEST AO"(Russia) was used. This kit is based on the quantitative determination of the above-mentioned cytokine in human blood serum using an immunoenzymatic assay. For data processing, MS Excel (2016) computer program was used. The arithmetic mean and standard deviation ( $M \pm m$ ) of all data in the following tables were calculated. To determine the significance of the difference between groups Student's paired and unpaired t-tests for quantitative indices. Correlation analysis was done using Pearson's correlation coefficient and confidence tables. Differences were considered to be statistically significant when  $p < 0.05$ .

Analysis of the study results. It is of great practical importance to evaluate inflammatory processes and permeability in the intestines of patients with COVID-19 and to restore it. For this purpose, we conducted a series of special biochemical examinations in our patients before the treatment procedures and studied the correlations between them.


**Figure 1. Correlation between interleukin-6 and calprotectin in patients clinically recovered from Covid-19.**



The increase of cytokines in the blood of patients infected with Covid-19 has been found in a large number of observations. Even the term "cytokine storm" has been coined in medicine to describe the cause of death of patients suffering from coronavirus in many cases. However, until now, there is not enough information on the dynamic changes of inflammatory cytokines, in particular interleukin-6, in patients who have clinically recovered from COVID-19. Moreover, their relationship with inflammatory markers in the intestinal wall, in particular calprotectin, has not been studied. In our observation, the reliable positive correlation between interleukin-6 and calprotectin confirms that inflammatory cytokines persist for a long time and cause inflammatory processes in intestinal walls even in patients who have clinically recovered from coronavirus infection (Fig. 1).

Calprotectin values were  $114.4 \pm 15.88 \mu\text{g/g}$  and  $68.23 \pm 12.64 \mu\text{g/g}$  in the main and control groups, respectively ( $p < 0.05$ ; Figure 2). High levels of calprotectin confirm the persistence of inflammatory processes in the intestines even after patients recover from the systemic effects of the coronavirus infection.

**Figure 2. Interleukin-6 and calprotectin levels of patients of the main (who have had Covid-19) and the control (who haven't had the infection) groups (\* -  $p < 0.05$ )**



In addition to the above, serum interleukin-6 levels were on average  $20.16 \pm 1.44 \text{ mmol/l}$  in patients who have had and "relatively recovered" from Covid-19, and  $11.25 \pm 1.4 \text{ mmol/l}$  in patients in the control group, differences were significant ( $p < 0.05$ ; Fig. 2).

This confirms that inflammatory cytokines remain elevated not only during the acute period of the disease, but also after clinical recovery and means that patients need rehabilitation measures.

**Conclusion:** The coronavirus infection directly affects the epithelia of the mucous membrane of the gastrointestinal tract, causing inflammatory processes. These changes cause an increase in inflammatory cytokines and the development of severe pathological conditions in organs. High levels of inflammatory cytokines and its reliable positive correlation with calprotectin in patients "relatively recovered" from COVID-19 with no detectable immunoglobulin M were confirmed in our study as well. Thus, it was found that in the patients who had undergone COVID-19 and clinically recovered from it the levels of calprotectin in feces and interleukin-6 in the blood were significantly higher compared to the not infected. This indicates that the inflammatory process persists in their body for a long time and patients need rehabilitation measures.

## REFERENCES

1.Chan K.H., Poon L.L., Cheng V.C., Guan Y., Hung I.F., Kong J., et al. Detection of SARS coronavirus in patients with suspected SARS. *Emerg Infect Dis.* 2004;10(2):294-

9. <https://doi.org/10.3201/eid1002.030610>.

2.Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce, et al. First case of 2019 novel coronavirus in the United States. *N Engl J Med.* 2020 Mar 5;382(10):929-36. <https://doi.org/10.1056/NEJMoa2001191>.

3.Liang W., Feng Z., Rao S., Xiao O., Xue X., Lin Z., et al. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. *Gut.* 2020;69(6):1141-43. <https://doi.org/10.1136/gutjnl-2020-320832>.

4.Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020; 395(10224):565-74. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8).

5.Pan L., Mu M., Ren H. G., Yang P., Sun Y. Wang R., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. *Am J Gastroenterol.* 2020;115(5):766-73. <https://doi.org/10.14309/ajg.0000000000000620>.

6.Tang A., Tong Z.D., Wang H.L., Dai Y.X., Li K.F., Liu J.N., et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. *Emerg Infect Dis.* 2020;26(6):1337-39. <https://doi.org/10.3201/eid2606.200301>.

7.To K.K.W., Tsang O.T.Y., Yip C.C.Y., Chan K.H., Wu T.C., Chan J.V.C., et al. Consistent detection of 2019 novel coronavirus in saliva. *Clin Infect Dis.* 2020; 12:149. <https://doi.org/10.1093/cid/ciaa149>.

8.Ungaro R.C., Sullivan T., Colombel J.-F., Patel G. What should gastroenterologists and patients know about COVID-19? *Clin Gastroenterol Hepatol.* 2020;18(7):1409-11. <https://doi.org/10.1016/j.cgh.2020.03.021> (8-15, 20).

9.Wu Y., Guo C., Tang L., Hong Z., Zhou J., Dong X., et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020;5(5):434-35. [https://doi.org/10.1016/S2468-1253\(20\)30083-2](https://doi.org/10.1016/S2468-1253(20)30083-2).

10.Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology.* 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055. Epub 2020 Mar 3. PMID: 32142773; PMCID: PMC7130181.

11. Young B.E., Ong S.W.X., Kalimuddin S., Low J.G., Tan S.J., Loh J., et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. *JAMA*. 2020;323(15):1488-94. <https://doi.org/10.1001/jama.2020.3204>.

12. Zhang W., Du R.H., Li B., Xu D., Wang J., Li Z., Lin J. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. *Emerg Microbes Infect* 2020;9(1):386-9. <https://doi.org/10.1080/22221751.2020.1729071>.

13. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579(7798):270-273. <https://doi.org/10.1038/s41586-020-2012-7>.

**Информация об авторх:**

© ИСМОИЛОВА М.И. - Ферганский медицинский институт общественного здоровья, г. Фергана.

**Muallif haqida ma'lumot:**

© ISMOILOVA M.I.- Farg'ona jamoat salomatligi tibbiyot instituti, Farg'ona sh.

**Information about the authors:**

© ISMOILOVA M.I.- Fergana medical institute of public health, Fergana.